Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression.
The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers.
Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers.
Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $18.4M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Vedanta Ca... | vedacap.co... |
| - | Global Sou... | globalsour... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.02.2017 | Series B | $18.4M | - |
Mentions in press and media 5
| Date | Title | Description |
| 07.03.2024 | Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results | - |
| 05.01.2022 | Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma | The company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib The FDA also provided positive feedback... |
| 04.11.2021 | Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results | Progressed the development of zilovertamab (formerly cirmtuzumab) for the treatment of patients with mantle cell lymphoma, including ongoing interactions with the US FDA on potential registration pathways Identified ONCT-808 as the lead can... |
| 04.11.2021 | Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results - Form 8-K | Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results - Progressed the development of zilovertamab (formerly cirmtuzumab) for the treatment of patients with mantle cell lymphoma, including ongoing interaction... |
| 22.02.2017 | Oncternal Closes $18.4M Series B Financing | Oncternal Therapeutics, Inc., a San Diego, CA-based clinical-stage biotechnology company developing therapies for both rare and common malignancies, closed an $18.4m Series B financing. The investors were not disclosed. Led by James Breitme... |